BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)
BRUKINSA is the only Bruton’s Tyrosine Kinase (BTK) inhibitor to achieve superiority over IMBRUVICA® (ibrutinib) in relapsed/refractory CLL. BRUKINSA also showed superiority to chemoimmunotherapy in treatment naive CLL. BRUKINSA had a favorable safety profile, including lower rates of atrial fibrillation/flutter compared with IMBRUVICA. CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--(BUSINESS…